Literature DB >> 2965132

HPLC quantitation of the six main components of teicoplanin in biological fluids.

F Jehl1, H Monteil, A Tarral.   

Abstract

Teicoplanin, a new glycopeptide antibiotic belonging to the same class as vancomycin, is a mixture of six main components, designated A3, A2-1, A2-2, A2-3, A2-4 and A2-5. An assay method by higher performance liquid chromatography (HPLC) has been devised to separate and monitor each of these components in blood and urine.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2965132     DOI： 10.1093/jac/21.suppl_a.53

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  9 in total

1.  Population pharmacokinetic study of teicoplanin in severely neutropenic patients.

Authors:  O Lortholary; M Tod; N Rizzo; C Padoin; O Biard; P Casassus; L Guillevin; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

2.  Teicoplanin in cardiac surgery: intraoperative pharmacokinetics and concentrations in cardiac and mediastinal tissues.

Authors:  C Martin; P Bourget; M Alaya; A Sertin; C Atlani; K Ennabli; R Said
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of teicoplanin.

Authors:  M Rowland
Journal:  Clin Pharmacokinet       Date:  1990-03       Impact factor: 6.447

Review 4.  Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D M Campoli-Richards; R N Brogden; D Faulds
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

5.  Efficacy and pharmacokinetics of teicoplanin in hemodialysis patients.

Authors:  B Beckers; H P Brodersen; R M Stolpmann; G Jansen; D Larbig
Journal:  Infection       Date:  1993 Jan-Feb       Impact factor: 3.553

6.  Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients.

Authors:  C Leport; C Perronne; P Massip; P Canton; P Leclercq; E Bernard; P Lutun; J J Garaud; J L Vilde
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

7.  Clinical evaluation of teicoplanin fluorescence polarization immunoassay.

Authors:  M J Rybak; E M Bailey; V N Reddy
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

Review 8.  Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D H Peters
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

9.  Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of experimental endocarditis due to Enterococcus faecium.

Authors:  B Fantin; R Leclercq; M Arthur; J Duval; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.